A detailed history of Glen Eagle Advisors, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 100 shares of BNTX stock, worth $11,394. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Holding current value
$11,394
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jul 03, 2024

BUY
$88.96 - $112.35 $8,896 - $11,235
100 New
100 $9.23 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.7B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.